Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on...

Descripció completa

Dades bibliogràfiques
Autors principals:	Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R
Format:	Journal article
Idioma:	English
Publicat:	2005

Ítems similars

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
per: Watson, C, et al.
Publicat: (2004)

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
per: Calne, R, et al.
Publicat: (1999)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
per: Clatworthy, MR, et al.
Publicat: (2009)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
per: Friend, P, et al.
Publicat: (1988)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
per: Friend, P, et al.
Publicat: (1991)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
per: Friend, P, et al.
Publicat: (1989)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
per: Calne, R, et al.
Publicat: (1998)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
per: Hale, G, et al.
Publicat: (1986)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
per: Chakrabarti, S, et al.
Publicat: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
per: Hale, G, et al.
Publicat: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
per: Phuong-Thu T Pham, et al.
Publicat: (2008-12-01)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
per: Muthusamy, A, et al.
Publicat: (2011)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
per: Clatworthy, MR, et al.
Publicat: (2007)

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
per: Tighe, H, et al.
Publicat: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1994)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1988)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
per: Rebello, P, et al.
Publicat: (1999)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
per: Muthusamy, A, et al.
Publicat: (2007)

CAMPATH: from concept to clinic.
per: Waldmann, H, et al.
Publicat: (2005)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
per: Lundin, J, et al.
Publicat: (2001)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
per: Waldmann, H, et al.
Publicat: (1987)

CAMPATH-1 antibodies in stem-cell transplantation.
per: Hale, G, et al.
Publicat: (2001)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
per: Muthusamy, A, et al.
Publicat: (2008)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
per: Waldmann, H, et al.
Publicat: (1985)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
per: Muthusamy, A, et al.
Publicat: (2007)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
per: Maria Kadma da Silva Carriço, et al.
Publicat: (2003-06-01)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
per: Waldmann, H, et al.
Publicat: (1985)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
per: Dyer, M, et al.
Publicat: (1990)

Specificity of monoclonal antibody Campath-1.
per: Hale, G, et al.
Publicat: (1988)

Campath Induction and Steroid Avoidance in Pancreas Transplantation - A Single Centre Experience in 231 Patients.
per: Muthusamy, A, et al.
Publicat: (2009)

CAMPATH-1H in inflammatory arthritis.
per: Watts, R, et al.
Publicat: (1993)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
per: Fibbe, W, et al.
Publicat: (1993)

Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.
per: Friend, P, et al.
Publicat: (1987)

The CAMPATH-1 antigen (CDw52).
per: Hale, G, et al.
Publicat: (1990)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
per: Hale, G, et al.
Publicat: (1998)

RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL)
per: Apperley, J, et al.
Publicat: (1985)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
per: Hale, G, et al.
Publicat: (1988)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
per: Russell, N, et al.
Publicat: (1999)

CAMPATH-IH in multiple sclerosis.
per: Moreau, T, et al.
Publicat: (1996)